Investor Overview

Stock Information
Loading data...

Shares outstanding

100,328,686 (as of 08/08/2024)

Press Releases
Sep 20, 2024

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A Specific Deletion in Mitochondrial DNA...

Sep 9, 2024

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB:...

Aug 20, 2024

As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact...

Aug 14, 2024

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — —...

Jul 25, 2024

Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc....

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel.

  • The U.S. contraceptive market was estimated at $8.3 billion as of 2022.
  • Every 1% market share of the 43.3 million women in Evofem's addressable market represents more than $450 million in net product sales for the Company.
  • 2023 marked the third consecutive year of Phexxi net sales growth.  

In July 2024, Evofem acquired global rights to its second women’s health product, SOLOSEC® (secnidazole) 2g oral granules.  This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.  Evofem plans to re-launch SOLOSEC in the U.S. in the second half of 2024, leveraging its commercial infrastructure and strong physician relationships.

Evofem intends to expand the global reach of its products and further increase its commercial potential through ex-U.S. licenses. Phexxi is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

On December 11, 2023, Evofem and Aditxt, Inc. (Nasdaq: ADTX) entered into the Agreement and Plan of Merger by and between the companies (the "Merger Agreement"). On May 3, 2024, Evofem and Aditxt reinstated the Merger Agreement, as amended, and entered into the Fourth Amendment to the Agreement and Plan of Merger. The companies are working toward close in the second half of 2024.

Evofem believes the proposed Transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise.

The Company's common stock currently trades on the OTCQB Venture Market under the ticker symbol "EVFM".

Featured Event
Wednesday, September 18, 2024

View All

Latest Financial Results

Q2 ended June 30, 2024

Earnings Release
10-Q Filing
XBRL